American Journal of Clinical Dermatology

Papers
(The TQCC of American Journal of Clinical Dermatology is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Alcohol and Smoking Cessation as Potential Modulators for Smoking-Associated Psoriasis Risk in Postmenopausal Women: The Women’s Health Initiative212
The Current State of Systemic Therapy of Metastatic Uveal Melanoma164
Role of Inflammation and Cytokine Dysregulation in Depression in Patients with Inflammatory Skin Conditions111
Prognostic Biomarkers in Evolving Melanoma Immunotherapy95
Economic Burden of Chronic Hand Eczema: A Review91
Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments87
New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review85
Disease Duration in Patients Recruited to Psoriasis Phase III Trials: A Systematic Review84
The Burden of Pediatric Psoriasis: A Systematic Review81
Deciphering the Etiologies of Adult Erythroderma: An Updated Guide to Presentations, Diagnostic Tools, Pathophysiologies, and Treatments79
Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know63
Predicting the Time to Relapse Following Withdrawal from Different Biologics in Patients with Psoriasis who Responded to Therapy: A 12-Year Multicenter Cohort Study61
Performance of Staging Systems for Non-head and Neck Cutaneous Squamous Cell Carcinoma59
Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data59
Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials59
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks58
Agreement Between Nail Psoriasis Severity Index Scores by a Convolutional Neural Network and Dermatologists: A Retrospective Study at an Academic New York City Institution57
Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology57
Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?56
Pathophysiology of Generalized Pustular Psoriasis55
Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review52
Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroi52
Correction to: Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion51
Disease Modification in Psoriasis: Future Prospects for Long-Term Remission51
Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation50
Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”49
Drug Survival of Oral Retinoids in Hidradenitis Suppurativa: A Real-Life Cohort Study49
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment47
Lessons Learned from Orthopedics: A Call to Action for More Rigorous Platelet-Rich Plasma Hair Loss Clinical Trials44
Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature43
Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry42
Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management42
Skin Cancer in People of Color: A Systematic Review42
Real-World Evidence on Dose Spacing of IL-23 Inhibitors in the Treatment of Psoriasis42
A Practice Approach to Acne Fulminans in Adolescents41
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis39
Ethnic Differences of Palmoplantar Pustulosis: A Systematic Review39
Atopic Dermatitis: Fertility, Pregnancy, and Treatment Perspectives39
Correction to: AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment Hist38
Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment38
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases36
Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa36
Scratching the Surface: A Comprehensive Guide to Understanding and Managing Vulvovaginal Itching34
A Review of the Etiologies and Key Clinical Features of Secondary Hyperhidrosis34
Oral Lichen Planus: An Update on Diagnosis and Management34
Multiple Keratoacanthomas Associated with Genetic Syndromes: Narrative Review and Proposal of a Diagnostic Algorithm34
Management and Long-Term Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review33
Patient and Public Involvement in Dermatology Research: A Review32
Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates31
Frontal Fibrosing Alopecia: An Update30
Commentary on “Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology”29
Tree-Based Machine Learning to Identify Predictors of Psoriasis Incidence at the Neighborhood Level: A Populational Study from Quebec, Canada29
Individualized Neoantigen-Directed Melanoma Therapy28
Differential Diagnosis, Prevention, and Treatment of mpox (Monkeypox): A Review for Dermatologists27
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)27
The Burden of Acne Vulgaris on Health-Related Quality of Life and Psychosocial Well-Being Domains: A Systematic Review27
JAK Inhibitors and Inflammatory Nail Disorders: A Systematic Review of Clinical Outcomes and Therapeutic Potential27
Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study26
AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History26
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials26
Advancing Precision Medicine in Inflammatory Skin Disease26
Autoimmune and Cutaneous Inflammatory Comorbidities in Adult-Onset Morphea in the All of Us Research Program25
Targeting Inflammation in Acne: Current Treatments and Future Prospects25
Comment on: “Eyebrow and Eyelash Alopecia: A Clinical Review”25
Exploring Suzetrigine's Role in Dermatologic Surgery: A Novel Nonopioid Analgesic for Postoperative Pain Management24
Burden to Partners of People with Psoriasis: Results from the FamilyPso International Study24
Safety of Alopecia Treatments in Patients with Breast Cancer and High-Risk Women: A Review24
Intravenous Immunoglobulin Therapy for Pyoderma Gangrenosum: A Multicenter Retrospective Analysis in 81 Patients24
Management of Acne in Pregnancy24
Acknowledgement to Referees24
Approach to the Atypical Wound23
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results23
Cutaneous Small Vessel Vasculitis: A Practical Guide to Diagnosis and Management22
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study22
Beyond the Herald Patch: Exploring the Complex Landscape of Pityriasis Rosea22
Identifying and Treating Ocular Manifestations in Psoriasis22
Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey22
Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion 22
Systemic Versus Topical Corticosteroids in the Treatment of DRESS: A Retrospective Cohort Study Followed by a Meta-Analysis22
Publisher Correction to: Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials21
Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year21
Is There a Place for Biologics in Acne?21
Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians21
Treatment Strategies for Chronic Pruritus and Eczema/Dermatitis in Older Adults Under the Category of Chronic Eczematous Eruptions of Aging (CEEA)20
The 25th World Congress of Dermatology, Singapore, 3–8 July, 2023: Research Highlights20
Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-220
0.70773696899414